These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Prostanoids receptors signaling in different diseases/cancers progression. Yang Y; Tang LQ; Wei W J Recept Signal Transduct Res; 2013; 33(1):14-27. PubMed ID: 23327583 [TBL] [Abstract][Full Text] [Related]
4. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Hata AN; Breyer RM Pharmacol Ther; 2004 Aug; 103(2):147-66. PubMed ID: 15369681 [TBL] [Abstract][Full Text] [Related]
5. International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Woodward DF; Jones RL; Narumiya S Pharmacol Rev; 2011 Sep; 63(3):471-538. PubMed ID: 21752876 [TBL] [Abstract][Full Text] [Related]
6. 5-HT(6) receptor modulators: a patent update. Part 2. Diversity in heterocyclic scaffolds. Ivachtchenko AV; Ivanenkov YA; Skorenko AV Expert Opin Ther Pat; 2012 Oct; 22(10):1123-68. PubMed ID: 22957857 [TBL] [Abstract][Full Text] [Related]
7. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Kiriyama M; Ushikubi F; Kobayashi T; Hirata M; Sugimoto Y; Narumiya S Br J Pharmacol; 1997 Sep; 122(2):217-24. PubMed ID: 9313928 [TBL] [Abstract][Full Text] [Related]
8. Roles of prostanoids in the pathogenesis of cardiovascular diseases: Novel insights from knockout mouse studies. Yuhki K; Kojima F; Kashiwagi H; Kawabe J; Fujino T; Narumiya S; Ushikubi F Pharmacol Ther; 2011 Feb; 129(2):195-205. PubMed ID: 20920529 [TBL] [Abstract][Full Text] [Related]
9. Affinities, selectivities, potencies, and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: focus on DP class prostanoids. Sharif NA; Crider JY; Xu SX; Williams GW J Pharmacol Exp Ther; 2000 May; 293(2):321-8. PubMed ID: 10772998 [TBL] [Abstract][Full Text] [Related]
10. Prostanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veins. Walch L; de Montpreville V; Brink C; Norel X Br J Pharmacol; 2001 Dec; 134(8):1671-8. PubMed ID: 11739243 [TBL] [Abstract][Full Text] [Related]
11. CRTH2 and D-type prostanoid receptor antagonists as novel therapeutic agents for inflammatory diseases. Schuligoi R; Sturm E; Luschnig P; Konya V; Philipose S; Sedej M; Waldhoer M; Peskar BA; Heinemann A Pharmacology; 2010; 85(6):372-82. PubMed ID: 20559016 [TBL] [Abstract][Full Text] [Related]
13. Exogenous but not endogenous prostanoids regulate cytokine secretion from murine bone marrow dendritic cells: EP2, DP, and IP but not EP1, EP3, and FP prostanoid receptors are involved. Józefowski S; Bobek M; Marcinkiewicz J Int Immunopharmacol; 2003 Jun; 3(6):865-78. PubMed ID: 12781703 [TBL] [Abstract][Full Text] [Related]
14. The molecular biology and ocular distribution of prostanoid receptors. Woodward DF; Regan JW; Lake S; Ocklind A Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S15-21. PubMed ID: 9154272 [TBL] [Abstract][Full Text] [Related]